Jaju Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Jaju Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, growt…

2002-09-17 New Delhi, Delhi Active Unlisted Active Compliant
Share
Connect MCP
JP Jaju Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Jaju Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
90/100
Trust Score
Low Risk

Jaju Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 90/100. Jaju Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2002, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 13 Aug 2026 from the latest processed filings. Jaju Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
90/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
75/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 75/100 Low Risk
  • Moderate gearing (D/E 38%).
  • Profitable - internal accruals available.

Charges position: 2 open (11.00 Lakh) · 1 satisfied (9.50 Lakh).

Banking relationships (from registered charges)
LenderChargesAmount
Punjab National Bank3 48.0 cr
Compliance Score: 93/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
PRAMOD KUMAR JAJU 01234567 Director 01/04/2018 6 yrs Approved
SAURABHRAJ JAJU 01234567 Director 01/04/2018 6 yrs Approved
SAHARSH JAJU 01234567 Director 01/04/2018 6 yrs Approved
POOJA JAJU 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • 2 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
Operating for 23+ years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 24% in a year.
2 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment84/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 11.00 Lakh already registered.
  • Compliance record supports lending.
Investor view84/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
29 Sep 2025
Director ceased
SAHARSH JAJU
Director ceased
POOJA JAJU
31 Mar 2025
Latest balance sheet
Filed with ROC
05 Aug 2024
Director appointed
POOJA JAJU (Director)
01 Apr 2024
Director appointed
SAHARSH JAJU (Director)
13 Feb 2013
Securities allotted
4300 Equity Shares Without Differential Rights - 6.45 Lakh raised
17 Jan 2013
Securities allotted
4300 Equity Shares Without Differential Rights - 6.45 Lakh raised
03 May 2010
Securities allotted
5000 Equity Shares Without Differential Rights - 5.00 Lakh raised
31 Mar 2010
Securities allotted
5000 Equity Shares Without Differential Rights - 5.00 Lakh raised
29 Mar 2010
Charge created
Punjab National Bank - 6.00 Lakh
Charge created
Punjab National Bank - 5.00 Lakh
30 Apr 2009
Securities allotted
20000 Equity Shares Without Differential Rights - 20.00 Lakh raised
31 Mar 2009
Securities allotted
20000 Equity Shares Without Differential Rights - 20.00 Lakh raised
13 Nov 2007
Charge satisfied
Punjab National Bank
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Chemicure Laboratories Private Limited U85195RJ1983PTC002673 Udaipur, Rajasthan, India
Kuemen Laboratories Private Limited U74899DL1991PTC044697 New Delhi, Delhi, India
Floral Aromatics(India) Private Limited U24244MH2005PTC157429 Bhiwandi, Maharashtra, India
Supreme Transformer Private Limited U31102MH1996PTC104332 Thane, Maharashtra, India
Real Gas And Chemicals Private Limited U24111PB1996PTC018304 Patiala, Punjab, India
Sage Herbals Private Limited U24247DL2008PTC175110 New Delhi, Delhi, India
Chemax Multikotes (India) Private Limited U24110MH2003PTC141379 Navi Mumbai, Maharashtra, India
Jimit Medico Surgicals U33110GJ2013PTC074134 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Jaju Pharmaceuticals Private Limited before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Jaju Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 75/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Jaju Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 90/100, distress signals and MSME payment-delay disclosures - know whether Jaju Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Jaju Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Jaju Pharmaceuticals Private Limited an active company?

Jaju Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 93/100 (Low Risk).

Is Jaju Pharmaceuticals Private Limited financially healthy?

Jaju Pharmaceuticals Private Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Jaju Pharmaceuticals Private Limited?

Its overall Trust Score is 90/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Jaju Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Jaju Pharmaceuticals Private Limited have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Jaju Pharmaceuticals Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).

Is it risky to lend to Jaju Pharmaceuticals Private Limited?

Its Credit Risk Score is 75/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.